Live Discussion: AI and Precision Medicine in Solid Tumors

Live Discussion: AI and Precision Medicine in Solid Tumors

AI and Precision Medicine in Solid Tumors

Join Dr. Anitha Singareddy, Dr. Andrew Patterson, and Julia O’Lynn during a live discussion about blinded independent central review in oncology clinical trials and volumetrics and radiomics in solid tumors.

Date: 10th May 2022, 11 am EST

To register, follow below web link:

AI and Precision Medicine in Solid Tumors (webinarjam.com)

In this live discussion, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, reader performance monitoring, and factors leading to site central discordance. Our experts will cover different radiographic response assessment criteria, such as RECIST 1.1, irRECIST, Choi etc.

Join our live discussion with experts on how to incorporate an efficient imaging strategy and volumetrics and radiomics into drug development programs.

​​​​​​​Key discussion points:

  • Imaging endpoints in oncology and regulatory requirements
  • Site vs central reading: benefits, challengers, and opportunities
  • Assessment criteria in solid tumors: choosing the right criteria
  • Volumetrics and radiomics in solid tumors

Presenter: Dr. Anitha Singareddy:
Dr. Singareddy is a board-certified physician having more than 13 years of experience in clinical research, CRO industry and medical imaging as well as extensive experience in medical imaging in the solid tumour portfolio using RECIST 1.1, iRECIST and other oncology review criteria.

Presenter: Dr. Andrew Patterson:
Dr Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.

Moderator: Julia O’Lynn:
With 20+ years of expertise in targeted drug development and advanced radiologic imaging, Julia advises life science companies on how to accelerate drug development and commercialization.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Live Discussion: AI and Precision Medicine in Neuro-Oncology

Live Discussion: AI and Precision Medicine in Neuro-Oncology

AI and Precision Medicine in Neuro-Oncology

Join Prof. Sotirios Bisdas, Dr. Andrew Patterson, and Julia O’Lynn during a live discussion about the imaging, design, and execution of GBM clinical programs.   

Date: 31th March 2022, 11 am EST

Reach out to our imaging experts at imaging.experts@ia-grp.com if you would like a link to watch a recording of this live discussion.

About the Webinar:

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

Join our live discussion with experts on how to incorporate an efficient imaging strategy and AI into drug development programs.

Key discussion points:

  • Modern trial infrastructure
  • Power of Artificial Intelligence (AI)
  • RANO, mRANO, iRANO: Choosing the right criteria
  • Impacting patient outcomes

Presenter: Dr. Sotirios Bisdas:
Head of Neuro-Oncology and Neurology clinical research at IAG, neuroradiologist, Associate Professor at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. Dr. Bisdas is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases.

Presenter: Dr. Andrew Patterson:
Dr Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.

Moderator: Julia O’Lynn:
With extensive expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials. Specializing in neuro-oncology, she helps build biotech partnerships exploring how advanced analysis, AI, and precision medicine can determine early efficacy.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: Developing OA Drugs in Times of ”Rapidly Progressive OA”

Webinar: Developing OA Drugs in Times of ”Rapidly Progressive OA”

Developing Osteoarthritis Drugs in Times of ”Rapidly Progressive Osteoarthritis”

Join Prof. Mikael Boesen, Dr. Lee Simon, Dr. Olga Kubassova, and Dr. Dimitri Kessler during a live webinar to discuss rapidly progressive osteoarthritis (RPOA) and challenges of designing and executing Osteoarthritis clinical trials.

Date: 17th March 2022, 11 am EST

To register, please click here or follow below web link:  https://event.webinarjam.com/register/82/5v7kybk9

About the Webinar:

The design of osteoarthritis (OA) clinical trials investigating novel OA drug therapeutics has always been challenging. In this webinar, we want to discuss a particular challenge of accounting for patients who may develop rapidly progressive osteoarthritis (RPOA). The etymology and epidemiology of RPOA are not yet well characterised. We nowadays know that the dramatic radiologic manifestations of RPOA can lead to diagnostic confusion with other arthropathies, infection, and osteonecrosis.

Design of a successful clinical trial must incorporate an imaging strategy that would allow to exclude patients who are at risk of developing RPOA, as this would have profound implications on the trial outcomes and safety of patients. It is therefore imperative to understand RPOA and how imaging can assist in defining patient eligibility prior to enrolment as well as monitoring patient safety during clinical trials.

Key discussion points:

  • Regulatory perspective and future directions in knee OA drug development
  • Observational radiographic features that may lead to prompt diagnosis of RPOA
  • Design of clinical trials of osteoarthritis and use of imaging in identifying RPOA

Presenter: Prof. Mikael Boesen:
Professor of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Prof. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.

Presenter: Dr. Lee Simon:
Rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharmaceutical companies on designing impactful clinical programs. Dr. Simon is a Principal Consultant and member of IAG’s Scientific Advisory Board.

Moderator: Dr. Olga Kubassova:
CEO of IAG, Image Analysis Group, Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, with AI, Machine Learning for fast objective early decisions in clinical trials.

Moderator: Dr. Dimitri Kessler:
A Senior Scientist at IAG, leading the musculoskeletal portfolio to support IAG’s bio-pharma clients in designing and delivering high-quality imaging trials. Dr. Kessler has a background in medical physics and a PhD in quantitative MRI with a focus on musculoskeletal imaging. He has a passion for medical imaging, analysis and AI.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: Power of Modern Trial Infrastructure for Accelerated Drug Development

Webinar: Power of Modern Trial Infrastructure for Accelerated Drug Development

Webinar: AI and Cloud – Power of Modern Trial Infrastructure for Accelerated Drug Development

Speed, quality, and cost of drug development depend on the robust clinical trial design, targeted patient selection and optimal efficacy assessments. Imaging is increasingly used in clinical trials to improve success rate and reveal early evidence of treatment impact.

IAG, Image Analysis Group is a leading medical imaging expert company driving the use of quantitative imaging as an early evidence for drug development. We improve speed and reproducibility of radiological reviews with Computer-Aided workflows and bring smart often AI driven methodologies to extract the full spectrum of information from medical images. Thus, giving biotech or pharma companies early powerful efficacy data in clinical trials.

In this webinar, we will present our proprietary cloud-based platform DYNAMIKA and show how it can increase efficiencies of traditional radiological reviews while integrating the best of advanced quantitative image analysis in clinical trials.

We will show how the flow of an imaging part of a clinical trial improves when operational teams can take advantage of automated data de-identification, built-in audit trail and notification system, automated quality control, and seamless workflows for all trial stakeholders.

Our therapeutic experts will show case studies of early drug evidence, trial enrichment and advanced treatment efficacy assessments from phase I-IV trials in oncology, neurology, and rheumatology.

This webinar will be interesting to those who are responsible for clinical trials operations, design of clinical trial protocols, imaging biomarker selection, patient recruitment and overall success of clinical programs.

Date and Time:

Friday, May 21 2021, 12 PM ET / 5 PM BST

Register on Xtalks

For questions or a replay, email imaging.experts@ia-grp.com

What you will learn:

  • De-risking clinical trials and accelerating drug development through efficient central imaging data management and centralized review.
  • Powering your trial with DYNAMIKA in a global multi-centre trial setting and delivering complex imaging trials.
  • AI-powered controls over your image data quality and radiological reviews.
  • Insight into the advanced data analytics / advanced quantitative approaches and their impact on the efficacy data.

Speakers:

Dr. Olga Kubassova, CEO of IAG and life science innovator, mathematician with expertise in actively managing innovation in life science companies, asset positioning, and strategy. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is an active researcher, with over 80 publications, books and book chapters. She is a scientific adviser to the UK government and EU funding bodies. Her ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG’s footprint and partnerships.

Prof. Jamshid Dehmeshki, CTO of IAG, is a software engineer with passion for medical imaging and 20+ years of mixed academic and commercial background. He is supporting IAG’s bio-pharma clients in the design and delivery of complex imaging trials that require the best in breed technology solutions. Jamshid’s experience is in enterprise development environments, medical device quality control, algorithm development and patenting novel approaches to medical image analysis. He is widely published academic and recognized speaker in the field of medical image analysis, data mining, algorithm development, medical image and video processing, mathematical, stochastic and forecasting modelling and numerical analysis. He has published more than 170 scientific research papers, five book chapters, and holds thirteen patents.

Prof. Mikael Boesen, MD, PhD, Head of Musculoskeletal Research at IAG, professor of radiology with focus on musculoskeletal imaging and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI on trials. He is an author of 130+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He brings together cross-therapeutic area expertise into musculoskeletal imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas.

Prof. Sotirios Bisdas, MD, PhD Head of Neuro-Oncology and Neurology at IAG, neuroradiologist, Senior Lecturer at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. He is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. He is actively involved in designing and publishing guidelines for the use of perfusion imaging in Oncology.

News
Events

Black & White Answers to Tough Questions in RA Drug Development

Black & White Answers to Tough Questions in RA Drug Development

Drug Development in Rheumatoid Arthritis: Black and White Answers to Tough Questions

We picked 3 hot topics and invited 3 outstanding speakers to join a live webinar focused on the drug development in Rheumatoid Arthritis (RA):

–    Unmet needs in RA drug development: do we still need new therapies?
–    Trial design: is clinical score enough?
–    Earlier decisions in RA drug development: how imaging and technology can support your clinical programs?

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

About the Webinar

While the rheumatoid arthritis drug pipeline is robust with over 240 molecules under study, many will drop off through natural attrition. It has been shown that only 40% of patients are ACR70 responders, which indicates a need for more effective treatment options.

The drug development process is complex, with greater focus being put on personalization of therapeutic strategies, both in the choice of molecules and their place in a patient treatment pathway.

This webinar will be a live discussion on several hot topics.

The moderator and the speakers will start with discussing the need for new therapies and what new therapies mean for the market.

The second topic will be focused on trial design, remission as an outcome, patient inclusion, trial enrichment and patient phenotyping.

The third topic is the use of imaging biomarkers and technology to achieve earlier decisions on treatment efficacy and practical aspects of RA clinical trials.

Dr. Lee Simon, MD
is a rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharma companies on designing impactful clinical programs. Dr. Simon is Principal Consultant and member of IAG’s Scientific Advisory Board.

Prof. Mikael Boesen, MD, PhD
is a professor of musculoskeletal imaging and hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speaker, and author of 130+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy. Prof. Boesen is IAG’s Lead for Musculoskeletal Clinical Research.

Prof. Philip Conaghan, MB, BS, Phd, FRACP, FRCP

is an academic rheumatologist and Director of the arthritis research Institute at the University of Leeds, UK. He has major research interests in understanding pathogenesis and improving the therapies for common arthritides, especially osteoarthritis, rheumatoid and psoriatic arthritis, with a focus on outcome measurement, modern imaging modalities, and optimising patient phenotypes for clinical trials and practice.

Moderator: Dr. Olga Kubassova
is CEO of IAG, Image Analysis Group, mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging and development of novel efficacy methodologies, with AI, Machine Learning for fast objective early decisions in clinical trials.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: The Role of Central Imaging in Successful Oncology Clinical Trials

Webinar: The Role of Central Imaging in Successful Oncology Clinical Trials

The Role of Central Imaging in Successful Oncology Clinical Trials

Today’s oncology R&D programs require precision in early go / no go decisions and clarity on the treatment impact.

Despite the FDA’s guidance on the imaging endpoint process, research shows that variability of site reads vs central reads is typically between 5-30%.

At IAG, we developed and implemented in over 400 trials a modern trial infrastructure for centralized data collection and central imaging review.

In this live webinar, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, with enterprise level platform DYNAMIKA that provides efficiencies, compliance, and security in data management. We will show how such a set-up allows to reduce variability in the reads, both radiology assessments and quantitative image review criteria.

We will discuss added efficiencies and cost savings enabled by DYNAMIKA. Our experts will cover advantages of quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, and Lugano.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

Key Discussion Points:

  • Importance of centralized image interpretation
  • Quantitative image analysis and radiological assessments:  the need of centralized imaging interpretations
  • Choosing the right imaging strategy and platform for your clinical trial.

Followed by a Q&A.

Speakers:

Dr Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer

Medical computer scientist by background, with strong experience in world-class academic research, biotechnology industry, pharma and investment. 10+ years of experience in the strategic use of medical imaging in the assessment of drug efficacy, trial conceptualizing, trial design and de-risking. Actively working with biotech companies to bridge the gap between academic research and their strategy for commercialization.

Sebastien Jacques, IAG’s Senior Project Manager

12+ years of experience in managing central imaging review for oncology clinical trials. Highly skilled in all aspect of Project Management, Software Engineering and Information Technology. Effective management of multiple oncology imaging projects and the project teams from study start-up to database lock with excellent operational planning and oversight, risks mitigation, resource, time and budget planning.

David Chia, CCO and Head of Bio-partnering

Senior executive with over 16 years of experience in strategic clinical development and operational analysis for biotechnology, pharma and life sciences companies. Expertise in creating and maintaining successful strategic partnerships between service providers and sponsors. Highly experienced in all aspects of clinical development including central imaging solutions.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: Advanced Imaging in Brain Cancer Therapy Development

Webinar: Advanced Imaging in Brain Cancer Therapy Development

Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer

Join Mariusz Olejniczak, CEO of WDP Pharmaceuticals, and Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, during a live webinar to discuss how advanced imaging can show early treatment effects in brain cancer.

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

About the Webinar:

WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. www.wpdpharmaceuticals.com

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

12th March Webinar: Speak to the IT Girls!

12th March Webinar: Speak to the IT Girls!

Meet IAG’s female technology leaders in a live discussion: sharing our story, career journey and aspirations.

The 8th March is International Women’s Day. This is the day for recognition and empowerment of our female leaders.

In 2021, this day marks nearly 12 months of the world’s covid troubles and importance of science.

2021 just calls to make this day extra special and talk about women in technology, science, and clinical research!

On this special day, we send our warmest wishes and want to invite you to join a live discussion with 4 inspirational female leaders of IAG. They will share their journey, career path and aspirations.

Dr. Olga Kubassova, IAG’s CEO and Founding Scientist, Dr. Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer, Julia O’Lynn, IAG’s Imaging Specialist and Technologist, and Romiesa Hagoug, IAG’s Sn Project Manager.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

Key Discussion Points:

  • My personal journey and joining clinical research industry,
  • What does technology, science and entrepreneurship mean to me,
  • My challenges and wins in day-to-day professional life,
  • My aspirations, ambitions, and advice I want to give to the future leaders.

Followed by a discussion and Q&A.

Who Should Attend:

A person of any age, any gender, any occupation who feels that they can draw insights from our life stories and our journey and make these useful to your family, colleagues or friends.

If you cannot attend, just register and you will receive a replay link!

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: Psoriatic Arthritis – Clinical Development Insights

Webinar: Psoriatic Arthritis – Clinical Development Insights

IAG’s Imaging Expert Team Discuss Psoriatic Arthritis – Clinical Development Insights

Join Dr. Olga Kubassova, Prof. Mikael Boesen, and Prof. Philip Mease during a live webinar to discuss how medical imaging can support targeted patient selection and more precise, objective assessment of the treatment impact.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

About the Webinar:

One of the challenges in treatment of patients with Psoriatic Arthritis  (PsA) is the disease’s variable presentation. PsA may present in several clinical domains, including synovitis, dactylitis, skin disease, nail disease, spine disease (spondylitis) and each of these domains has subtly different immunologic pathophysiology drivers. Thus, drug developers may find that their new therapies do very well in individual patients or within some of the domains. Medical Imaging, quantitative biomarkers coupled with efficiencies of modern scanners can support targeted patient selection and more precise objective assessment of the treatment impact.

Key discussion points:

  • How can we assess a new treatment efficacy through a clinical trial designed to give us a new comprehensive understanding of the treatment’s impact?
  • Are there biomarkers and imaging techniques which can help differentiate patients early?
  • State-of-the-art and emerging imaging techniques in trials of psoriatic arthritis
  • Imaging biomarkers – in patient selection and efficacy assessment of new treatments targeting PsA

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Mikael Boesen is currently employed as professor of radiology with focus on musculoskeletal imaging, and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and speaker as well as author of 120+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He also brings together cross-therapeutic area expertise into MSK imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas

About Prof. Philip Mease:
Dr. Mease is an international key opinion leader, researcher, educator and clinician who cares for patients at Seattle Rheumatology Associates, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His research interests include psoriatic arthritis and spondyloarthritis, rheumatoid arthritis, osteoarthritis, fibromyalgia and osteoporosis. He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism. He is a past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), active contributor to Outcome Measures in Rheumatology Clinical Trials (OMERACT) research group and serves in an educational and advisory role for the FDA.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Webinar: Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

Webinar: Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

 Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

Join Dr. Olga Kubassova, CEO and Prof. Mikael Boesen, Head of Musculoskeletal Imaging Research during a live webinar to discuss optimal use of imaging to empower clinical development of novel therapeutics in osteoarthritis and cartilage repair.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

About the Webinar:

A rising need for effective treatment that can both reduce pain and positively impact cartilage repair makes drug developers innovate in trial designs and use more informative biomarkers, including imaging.

Key discussion points:

  • Patient selection and appropriate use of imaging to account for comorbidities
  • FDA approved imaging endpoints for disease modification claims and use of AI in increasing their sensitivity
  • Novel imaging and scoring for osteoarthritis and cartilage repair clinical trials

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Prof. of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  www.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events